CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.
We investigated the expression of insulin-like growth factor-1 receptor (CD221) in normal, reactive and malignant plasma cells. We show that CD221 is aberrantly expressed on human myeloma cells, that higher levels of CD221 are observed in patients and human myeloma cell lines with the most aggressive 14q32 translocations, and that CD221 expression has a negative prognostic impact in patients with multiple myeloma.
Bataille
Régis
R
Robillard
Nelly
N
Avet-Loiseau
Hervé
H
Harousseau
Jean-Luc
JL
Moreau
Philippe
P
D001853:Bone Marrow / Q000737:chemistry; D045744:Cell Line, Tumor / Q000378:metabolism / Q000473:pathology; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics* / Q000648:ultrastructure; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics / Q000648:ultrastructure; D002894:Chromosomes, Human, Pair 4 / Q000235:genetics / Q000648:ultrastructure; D006801:Humans; D015993:Life Tables; D009101:Multiple Myeloma / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D014066:Palatine Tonsil / Q000737:chemistry; D010950:Plasma Cells / Q000737:chemistry* / Q000473:pathology; D011379:Prognosis; D017526:Receptor, IGF Type 1 / Q000096:biosynthesis* / Q000235:genetics; D016019:Survival Analysis; D014178:Translocation, Genetic
D009363:Neoplasm Proteins; D017526:Receptor, IGF Type 1